Earnings Feed
Start Free
Vaxcyte, Inc.·4

Mar 11, 5:23 PM ET

Wassil Jim 4

Research Summary

AI-generated summary

Updated

Vaxcyte (PCVX) COO Wassil Jim Sells 8,370 Shares

What Happened
Wassil Jim, Chief Operating Officer of Vaxcyte, reported disposals totaling 8,370 shares of Vaxcyte common stock for aggregate proceeds of about $493,277. Transactions include surrendering 975 shares on 2026-03-09 to cover tax withholding from RSU vesting (F1) and open-market sales of 2,427 shares and 4,968 shares on 2026-03-10 (S). The sales generated approximately $57,837 (surrender), $141,533 and $293,907, respectively. These are sales (not purchases) and therefore are routine dispositions rather than an accumulation of stock.

Key Details

  • Transaction dates: 2026-03-09 (975 shares surrendered for taxes), 2026-03-10 (2,427 and 4,968 shares sold).
  • Prices and values:
    • 975 shares @ $59.32 = $57,837 (tax withholding surrender; code F).
    • 2,427 shares weighted-average $58.32 = $141,533; sale prices ranged $57.725–$58.715 (F3).
    • 4,968 shares weighted-average $59.16 = $293,907; sale prices ranged $58.74–$59.575 (F4).
  • Total shares disposed: 8,370; total proceeds ≈ $493,277.
  • Shares owned after the transactions: not specified in the information provided in the summary (check the Form 4 for post-transaction holdings).
  • Footnotes of note:
    • F1: 975 shares were surrendered to the issuer to cover tax withholding on RSU vesting; no other locked-up shares were sold.
    • F2: The open-market sales were effected under a Rule 10b5-1 trading plan adopted December 9, 2025.
    • F3/F4: Reported prices are weighted averages; detailed per-price breakdowns are available upon request.
  • Filing timeliness: Form filed 2026-03-11 for transactions on 3/9–3/10 — appears to be filed within the standard two-business-day window.

Context

  • The 975-share surrender is a tax-withholding action tied to RSU vesting (common and not a market-directional signal).
  • The open-market sales were made under a pre-established 10b5‑1 plan (F2), which often means sales were scheduled in advance and should not be interpreted as an immediate personal view on the company.
  • Sales by executives are common for tax or diversification reasons; factual reporting here shows routine disposition rather than a purchase-based bullish signal.